MedTrace Logo

Evaluation of C13 Breath Test for Upper Gastrointestinal Bleeding in Patients Who Need Double Antiplatelet After PCI

NCT04012801 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2020-03-04

No results posted yet for this study

Summary

Hp infection is closely related to upper gastrointestinal bleeding in patients who need dual-antiplatelet after PCI. Taking anti-Hp treatment has the effect of reducing bleeding risk. Thus, we propose a scientific hypothesis: the C13 breath test may be used to assess the risk of upper gastrointestinal bleeding in patients who need dual- antiplatelet after PCI.

Conditions

  • Acute Myocardial Infarction

Interventions

DIAGNOSTIC_TEST

C13 breath test

C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • DZhang D Z, Associate Professor · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
24 Years
Max Age
93 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-07-31
Completion
2020-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04012801 on ClinicalTrials.gov